{"nctId":"NCT00451451","briefTitle":"Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis","startDateStruct":{"date":"2007-06"},"conditions":["Relapsing-Remitting Multiple Sclerosis"],"count":1417,"armGroups":[{"label":"BG00012 240 mg Twice Daily (BID)","type":"EXPERIMENTAL","interventionNames":["Drug: BG00012","Drug: Placebo"]},{"label":"BG00012 240 mg 3 Times Daily (TID)","type":"EXPERIMENTAL","interventionNames":["Drug: BG00012"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Glatiramer Acetate"]}],"interventions":[{"name":"BG00012","otherNames":["dimethyl fumarate","Tecfidera®"]},{"name":"Placebo","otherNames":[]},{"name":"Glatiramer Acetate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Unless otherwise specified, to be eligible to participate in this study, candidates must meet the following eligibility criteria at the time of the randomization:\n\nKey Inclusion Criteria:\n\n* Must have confirmed diagnosis of RRMS according to McDonald criteria #1-4\n* Must have a baseline EDSS between 0.0 and 5.0, inclusive.\n* Must have relapsing-remitting disease course.\n\nKey Exclusion Criteria:\n\n* Other chronic disease of immune system, malignancies, urologic, pulmonary, gastrointestinal disease\n* Pregnant or nursing women\n\nNote: Other protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Annualized Relapse Rate","description":"A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurologic evaluation committee.\n\nThe adjusted annualized relapse rate was calculated from a negative binomial regression model , adjusted for baseline Expanded Disability Status Scale (EDSS ) score(≤2.0 versus\\>2.0), age (\\<40 versus ≥40 years), region, and the number of relapses in the 1 year prior to enrollment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.401","spread":null},{"groupId":"OG001","value":"0.224","spread":null},{"groupId":"OG002","value":"0.198","spread":null},{"groupId":"OG003","value":"0.286","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of New or Newly Enlarging T2 Hyperintense Lesions","description":"The number of new or newly enlarging T2 hyperintense lesions at 2 years that developed in each subject compared to baseline assessed on brain magnetic resonance imaging (MRI) scans. The estimates of mean T2 hyperintense lesion count were calculated from a negative binomial regression model adjusted for region and baseline T2 hyperintense lesion volume.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":null},{"groupId":"OG001","value":"5.1","spread":null},{"groupId":"OG002","value":"4.7","spread":null},{"groupId":"OG003","value":"8.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of New T1 Hypointense Lesions","description":"The number of new T1 hypointense lesions at 2 years that developed in each subject compared to baseline assessed on brain magnetic resonance imaging (MRI) scans. The estimates of mean T1 hypointense lesion count were calculated from a negative binomial regression model adjusted for region and baseline T1 hypointense lesion volume.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null},{"groupId":"OG001","value":"3.0","spread":null},{"groupId":"OG002","value":"2.4","spread":null},{"groupId":"OG003","value":"4.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Relapsed","description":"A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurologic evaluation committee. The proportion of subjects with a relapse was estimated using the Kaplan-Meier method, which was based on the time-to-first-relapse survival distribution.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.410","spread":null},{"groupId":"OG001","value":"0.291","spread":null},{"groupId":"OG002","value":"0.241","spread":null},{"groupId":"OG003","value":"0.321","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS)","description":"EDSS is based on a standardized neurological exam and focuses on symptoms that commonly occur in MS. Scores range from 0.0 (normal) to 10.0 (death due to MS). Disability progression was defined as ≥ 1.0 point increase in subjects with a baseline EDSS of ≥1.0, or ≥1.5 point increase in subjects with a baseline EDSS=0, and required that the increase from baseline was confirmed ≥ 12weeks later. The proportion of subjects with confirmed (12-week) disability progression was estimated using the Kaplan-Meier method, which was based on the time-to-first-progression survival distribution","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.169","spread":null},{"groupId":"OG001","value":"0.128","spread":null},{"groupId":"OG002","value":"0.130","spread":null},{"groupId":"OG003","value":"0.156","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":79,"n":363},"commonTop":["MULTIPLE SCLEROSIS RELAPSE","FLUSHING","NASOPHARYNGITIS","HEADACHE","URINARY TRACT INFECTION"]}}}